Status:
RECRUITING
Analysis of Dermal Fibroblasts and Immune Cells During Systemic Sclerosis
Lead Sponsor:
University Hospital, Lille
Conditions:
Systemic Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
The pathophysiology of systemic sclerosis (SSc) is still poorly understood and there are no effective treatments for this disease. SSc is a heterogeneous disease with varying severity. The heterogenei...
Eligibility Criteria
Inclusion
- Man or woman over 18 years of age
- With a systemic sclerosis meeting the ACR-EULAR 2013 criteria Having signed an informed consent
- Being insured
Exclusion
- Syndrome of overlap with another connective tissue disease according to the international diagnostic criteria
- Immunosuppressive treatment within 12 months
- Dosage of current corticosteroid therapy ≥10mg/d
- Protected minors or adults
- Pregnant or breastfeeding women
- Deprived of their liberty
- Persons in emergency situations
- Persons who have refused or are unable to give informed consent
Key Trial Info
Start Date :
June 8 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05273138
Start Date
June 8 2022
End Date
June 1 2026
Last Update
December 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hop Claude Huriez Chu Lille
Lille, France, 59037